Reply to: "Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?"
- PMID: 32972731
- DOI: 10.1016/j.jhep.2020.08.026
Reply to: "Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?"
Conflict of interest statement
Conflict of interest LS reports grants and personal fees from Actelion, grants and personal fees from MSD, grants and personal fees from GSK, outside the submitted work. OS reports grants and personal fees from Actelion, grants and personal fees from Bayer, grants from GSK, grants and personal fees from MSD, personal fees from Ferrer, personal fees from Gossamer Bio, personal fees from Acceleron, outside the submitted work. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment on
-
Portopulmonary hypertension in the current era of pulmonary hypertension management.J Hepatol. 2020 Jul;73(1):130-139. doi: 10.1016/j.jhep.2020.02.021. Epub 2020 Mar 5. J Hepatol. 2020. PMID: 32145258
-
Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?J Hepatol. 2021 Jan;74(1):237-238. doi: 10.1016/j.jhep.2020.07.024. Epub 2020 Sep 16. J Hepatol. 2021. PMID: 32950270 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
